Psoriasis
FDA Approves ZORYVE® Foam 0.3%: A New Topical Option for Scalp and Body Psoriasis
In a significant development for psoriasis treatment, the U.S. Food
May 29, 2025
In a significant development for psoriasis treatment, the U.S. Food
Psoriasis, a complex, chronic autoimmune disease, affects approximately 125 million
Biologics that inhibit the pro-inflammatory cytokine IL-23 have long been
August is Psoriasis Awareness Month and a perfect opportunity to
This is a partner Blog from three of the Tarsus
Building on the previously demonstrated role of immunomodulation in chronic
August marks the beginning of Psoriasis Action Month, an observance
Prior research has demonstrated that neurotransmitters may play a role
Although psoriasis affects people of all skin colors, current estimates
The current understanding of atopic dermatitis pathophysiology is primarily derived
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
LiVDerm / South Beach Symposium
1801 N Military Trail, Ste 110
Boca Raton, FL, 33431
Copyright © 2025, LiVDerm. All Rights Reserved.
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
